The expansion of treatable eye diseases such as age related macula degeneration (AMD), diabetic retinopathy, glaucoma, retinal vein occlusion and uveitis has led to continuous use of non-invasive devices such as optical coherence tomography (OCT) in clinical domains to provide diagnosis and treatment paradigms. OCT is a high resolution, non invasive, optical imaging technology that recently has been evolved towards non-invasive imaging of the retinal vasculature without injection, ie of angiography (A) with no dye. Usually, vasculature is imaged by injecting the patient with a dye, indocyanine green (ICG) or Fluorescein. OCTA allows seeing the vessels with no dye. The current eye imaging systems are bulky, high cost, and require large surface area within clinical regions, meaning less space to see and treat patients. The OCT is a high-growth business, the number of OCT systems sold is soaring and demand is high, however, not every practice could afford to have one.
There is no deadline – applicants will be assessed on a rolling basis. The candidates must be in place in September 2019. For further information or informal enquiries, please contact Professor Adrian Podoleanu (A.G.H.Podoleanu@kent.ac.uk).